Mary Polan Biography and Net Worth

Director of QuidelOrtho


Dr. Mary Lake Polan serves as Independent Director of Quidel Corporation. Dr. Polan was an Adjunct Professor in the Department of Obstetrics and Gynecology at Columbia University School of Medicine from 2007 to 2014 and then in 2015 rejoined the Department of Obstetrics and Gynecology at Yale University School of Medicine as Clinical Professor. She was a Professor and Chair Emerita of the Department of Gynecology and Obstetrics at Stanford University School of Medicine where she served from 1990 to 2005. Dr. Polan received a B.A. degree from Connecticut College, a Ph.D. in Molecular Biophysics and Biochemistry and an M.D. from Yale University School of Medicine and her Master in Public Health from the University of California, Berkeley. Dr. Polan remained at Yale New Haven Hospital for her residency in Obstetrics and Gynecology, followed by a Reproductive Endocrine Fellowship. Dr. Polan was on the faculty at Yale University until 1990, when she joined Stanford University. Dr. Polan is a practicing clinical Reproductive Endocrinologist with a research interest in ovarian function and granulosa cell steroidogenesis. More recently, Dr. Polan’s interests have been in the interaction between the immune and endocrine systems: the role of monokines in reproductive events and gene expression in stress urinary incontinence as well as brain activation in human sexual function. Dr. Polan is also currently a director of Chembio Diagnostic Systems, Inc., a diagnostics company, NX Prenatal Inc, a private molecular diagnostics company and Or-Genix Therapeutics, Inc., a private, development-stage specialty women’s health and dermatology company.

What is Mary Lake Polan's net worth?

The estimated net worth of Mary Lake Polan is at least $896,217.08 as of September 3rd, 2021. Dr. Polan owns 19,987 shares of QuidelOrtho stock worth more than $896,217 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Polan may own. Learn More about Mary Lake Polan's net worth.

How do I contact Mary Lake Polan?

The corporate mailing address for Dr. Polan and other QuidelOrtho executives is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. QuidelOrtho can also be reached via phone at (800) 874-1517 and via email at [email protected]. Learn More on Mary Lake Polan's contact information.

Has Mary Lake Polan been buying or selling shares of QuidelOrtho?

Mary Lake Polan has not been actively trading shares of QuidelOrtho over the course of the past ninety days. Most recently, Mary Lake Ph D. Polan sold 1,525 shares of the business's stock in a transaction on Friday, March 18th. The shares were sold at an average price of $113.59, for a transaction totalling $173,224.75. Learn More on Mary Lake Polan's trading history.

Who are QuidelOrtho's active insiders?

QuidelOrtho's insider roster includes Michael Abney, Jr. (SVP), Douglas Bryant (CEO), Joseph Busky (CFO), William Ferenczy (SVP), Werner Kroll (SVP), Edward Michael (Director), Mary Polan (Director), Charles Slacik (Director), Randall Steward (CFO), and Matthew Strobeck (Director). Learn More on QuidelOrtho's active insiders.

Are insiders buying or selling shares of QuidelOrtho?

During the last year, QuidelOrtho insiders bought shares 2 times. They purchased a total of 8,183 shares worth more than $349,539.36. During the last year, insiders at the sold shares 25 times. They sold a total of 10,521,742 shares worth more than $374,367,521.97. The most recent insider tranaction occured on December, 11th when CEO Brian J Blaser bought 6,033 shares worth more than $249,886.86. Insiders at QuidelOrtho own 1.0% of the company. Learn More about insider trades at QuidelOrtho.

Information on this page was last updated on 12/11/2024.

Mary Lake Polan Insider Trading History at QuidelOrtho

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/18/2022Sell1,525$113.59$173,224.75View SEC Filing Icon  
9/3/2021Sell6,167$141.71$873,925.5719,987View SEC Filing Icon  
12/1/2020Sell11,000$192.25$2,114,750.0024,329View SEC Filing Icon  
11/6/2020Sell3,000$284.17$852,510.0035,329View SEC Filing Icon  
10/12/2020Sell11,743$275.83$3,239,071.6911,141View SEC Filing Icon  
5/11/2020Sell6,700$204.27$1,368,609.0027,484View SEC Filing Icon  
2/20/2019Sell14,449$70.17$1,013,886.339,207View SEC Filing Icon  
2/15/2019Sell13,772$65.12$896,832.6423,656View SEC Filing Icon  
8/27/2018Sell16,002$70.03$1,120,620.0629,653View SEC Filing Icon  
8/23/2018Sell3,886$70.01$272,058.8629,653View SEC Filing Icon  
See Full Table

Mary Lake Polan Buying and Selling Activity at QuidelOrtho

This chart shows Mary Lake Ph D Polan's buying and selling at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

QuidelOrtho Company Overview

QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $44.84
Low: $42.69
High: $45.97

50 Day Range

MA: $40.11
Low: $36.18
High: $44.84

2 Week Range

Now: $44.84
Low: $29.74
High: $75.86

Volume

1,870,816 shs

Average Volume

997,667 shs

Market Capitalization

$3.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11